These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 23331325)
1. Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis. Schön T; Lerm M; Stendahl O J Intern Med; 2013 Apr; 273(4):368-82. PubMed ID: 23331325 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
4. Adjunct immunotherapies for tuberculosis. Uhlin M; Andersson J; Zumla A; Maeurer M J Infect Dis; 2012 May; 205 Suppl 2():S325-34. PubMed ID: 22457298 [TBL] [Abstract][Full Text] [Related]
5. New treatment options for multidrug-resistant tuberculosis. Field SK; Fisher D; Jarand JM; Cowie RL Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676 [TBL] [Abstract][Full Text] [Related]
6. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Sacchettini JC; Rubin EJ; Freundlich JS Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742 [TBL] [Abstract][Full Text] [Related]
7. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related]
8. Present-day treatment of tuberculosis and latent tuberculosis infection. Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of drug resistance in Mycobacterium tuberculosis. Zhang Y; Yew WW Int J Tuberc Lung Dis; 2009 Nov; 13(11):1320-30. PubMed ID: 19861002 [TBL] [Abstract][Full Text] [Related]
10. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Ralph AP; Kelly PM; Anstey NM Trends Microbiol; 2008 Jul; 16(7):336-44. PubMed ID: 18513971 [TBL] [Abstract][Full Text] [Related]
11. Managing TB in the 21st century: existing and novel drug therapies. Guy ES; Mallampalli A Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385 [TBL] [Abstract][Full Text] [Related]
12. HIV infection and multidrug-resistant tuberculosis: the perfect storm. Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830 [TBL] [Abstract][Full Text] [Related]
14. Drug discovery in tuberculosis: a molecular approach. Mitra PP Indian J Tuberc; 2012 Oct; 59(4):194-206. PubMed ID: 23342539 [TBL] [Abstract][Full Text] [Related]
15. Overcoming the global crisis: "yes, we can", but also for TB ... ? Ottenhoff TH Eur J Immunol; 2009 Aug; 39(8):2014-20. PubMed ID: 19672895 [TBL] [Abstract][Full Text] [Related]
19. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. Mwaba P; McNerney R; Grobusch MP; O'Grady J; Bates M; Kapata N; Maeurer M; Zumla A Trop Med Int Health; 2011 Jul; 16(7):819-27. PubMed ID: 21489070 [TBL] [Abstract][Full Text] [Related]